{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:52:32Z","timestamp":1793083952249,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"8115","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,5,21]]},"DOI":"10.1038\/s41586-026-10342-9","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T15:03:47Z","timestamp":1775660627000},"page":"923-932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical application of base editing for treating \u03b2-thalassaemia"],"prefix":"10.1038","volume":"653","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0371-1719","authenticated-orcid":false,"given":"Yongrong","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaohui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Lin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenbin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaofeng","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3409-9665","authenticated-orcid":false,"given":"Annarita","family":"Miccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5389-3859","authenticated-orcid":false,"given":"Bei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5449-712X","authenticated-orcid":false,"given":"Xiaodun","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8833-7473","authenticated-orcid":false,"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-2899","authenticated-orcid":false,"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"10342_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/GIM.0b013e3181cd68ed","volume":"12","author":"A Cao","year":"2010","unstructured":"Cao, A. & Galanello, R. Beta-thalassemia. Genet. Med. 12, 61\u201376 (2010).","journal-title":"Genet. Med."},{"key":"10342_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/gim.2016.173","volume":"19","author":"R Origa","year":"2017","unstructured":"Origa, R. Beta-thalassemia. Genet. Med. 19, 609\u2013619 (2017).","journal-title":"Genet. Med."},{"key":"10342_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMra2021838","volume":"384","author":"AT Taher","year":"2021","unstructured":"Taher, A. T., Musallam, K. M. & Cappellini, M. D. \u03b2-Thalassemias. N. Engl. J. Med. 384, 727\u2013743 (2021).","journal-title":"N. Engl. J. Med."},{"key":"10342_CR4","doi-asserted-by":"publisher","unstructured":"Hardouin, G., Miccio, A. & Brusson, M. Gene therapy for \u03b2-thalassemia: current and future options. Trends Mol. Med. https:\/\/doi.org\/10.1016\/j.molmed.2024.12.001 (2025).","DOI":"10.1016\/j.molmed.2024.12.001"},{"key":"10342_CR5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41556-021-00671-4","volume":"23","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Eliminating base-editor-induced genome-wide and transcriptome-wide off-target mutations. Nat. Cell Biol. 23, 552\u2013563 (2021).","journal-title":"Nat. Cell Biol."},{"key":"10342_CR6","doi-asserted-by":"publisher","first-page":"3194","DOI":"10.1038\/s41596-023-00877-w","volume":"18","author":"W Han","year":"2023","unstructured":"Han, W. et al. Design and application of the transformer base editor in mammalian cells and mice. Nat. Protoc. 18, 3194\u20133228 (2023).","journal-title":"Nat. Protoc."},{"key":"10342_CR7","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/j.stem.2023.10.007","volume":"30","author":"W Han","year":"2023","unstructured":"Han, W. et al. Base editing of the HBG promoter induces potent fetal hemoglobin expression with no detectable off-target mutations in human HSCs. Cell Stem Cell 30, 1624\u20131639 (2023).","journal-title":"Cell Stem Cell"},{"key":"10342_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-5-11","volume":"5","author":"R Galanello","year":"2010","unstructured":"Galanello, R. & Origa, R. Beta-thalassemia. Orphanet J. Rare Dis. 5, 11 (2010).","journal-title":"Orphanet J. Rare Dis."},{"key":"10342_CR9","doi-asserted-by":"publisher","first-page":"a011700","DOI":"10.1101\/cshperspect.a011700","volume":"3","author":"SL Thein","year":"2013","unstructured":"Thein, S. L. The molecular basis of \u03b2-thalassemia. Cold Spring Harb. Perspect. Med. 3, a011700 (2013).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10342_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature09328","volume":"467","author":"M Cavazzana-Calvo","year":"2010","unstructured":"Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene therapy of human \u03b2-thalassaemia. Nature 467, 318\u2013322 (2010).","journal-title":"Nature"},{"key":"10342_CR11","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1056\/NEJMoa1705342","volume":"378","author":"AA Thompson","year":"2018","unstructured":"Thompson, A. A. et al. Gene therapy in patients with transfusion-dependent \u03b2-thalassemia. N. Engl. J. Med. 378, 1479\u20131493 (2018).","journal-title":"N. Engl. J. Med."},{"key":"10342_CR12","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1056\/NEJMoa2113206","volume":"386","author":"F Locatelli","year":"2022","unstructured":"Locatelli, F. et al. Betibeglogene autotemcel gene therapy for non-\u03b20\/\u03b20 genotype \u03b2-thalassemia. N. Engl. J. Med. 386, 415\u2013427 (2022).","journal-title":"N. Engl. J. Med."},{"key":"10342_CR13","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.stem.2024.04.021","volume":"31","author":"S Li","year":"2024","unstructured":"Li, S. et al. Modified lentiviral globin gene therapy for pediatric \u03b20\/\u03b20 transfusion-dependent \u03b2-thalassemia: a single-center, single-arm pilot trial. Cell Stem Cell 31, 961\u2013973 (2024).","journal-title":"Cell Stem Cell"},{"key":"10342_CR14","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1016\/S0140-6736(24)01884-1","volume":"404","author":"JL Kwiatkowski","year":"2024","unstructured":"Kwiatkowski, J. L. et al. Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype \u03b2-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial. Lancet 404, 2175\u20132186 (2024).","journal-title":"Lancet"},{"key":"10342_CR15","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1126\/science.1242088","volume":"342","author":"DE Bauer","year":"2013","unstructured":"Bauer, D. E. et al. An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level. Science 342, 253\u2013257 (2013).","journal-title":"Science"},{"key":"10342_CR16","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nature15521","volume":"527","author":"MC Canver","year":"2015","unstructured":"Canver, M. C. et al. BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis. Nature 527, 192\u2013197 (2015).","journal-title":"Nature"},{"key":"10342_CR17","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm.4170","volume":"22","author":"EA Traxler","year":"2016","unstructured":"Traxler, E. A. et al. A genome-editing strategy to treat \u03b2-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition. Nat. Med. 22, 987\u2013990 (2016).","journal-title":"Nat. Med."},{"key":"10342_CR18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1182\/blood-2011-09-382408","volume":"119","author":"KM Musallam","year":"2012","unstructured":"Musallam, K. M. et al. Fetal hemoglobin levels and morbidity in untransfused patients with \u03b2-thalassemia intermedia. Blood 119, 364\u2013367 (2012).","journal-title":"Blood"},{"key":"10342_CR19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.gde.2015.08.001","volume":"33","author":"DE Bauer","year":"2015","unstructured":"Bauer, D. E. & Orkin, S. H. Hemoglobin switching\u2019s surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin. Curr. Opin. Genet. Dev. 33, 62\u201370 (2015).","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10342_CR20","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1182\/blood-2016-01-678128","volume":"127","author":"MC Canver","year":"2016","unstructured":"Canver, M. C. & Orkin, S. H. Customizing the genome as therapy for the \u03b2-hemoglobinopathies. Blood 127, 2536\u20132545 (2016).","journal-title":"Blood"},{"key":"10342_CR21","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.tig.2018.09.004","volume":"34","author":"B Wienert","year":"2018","unstructured":"Wienert, B., Martyn, G. E., Funnell, A. P. W., Quinlan, K. G. R. & Crossley, M. Wake-up sleepy gene: reactivating fetal globin for \u03b2-hemoglobinopathies. Trends Genet. 34, 927\u2013940 (2018).","journal-title":"Trends Genet."},{"key":"10342_CR22","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1126\/science.1165409","volume":"322","author":"VG Sankaran","year":"2008","unstructured":"Sankaran, V. G. et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 322, 1839\u20131842 (2008).","journal-title":"Science"},{"key":"10342_CR23","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","volume":"25","author":"Y Wu","year":"2019","unstructured":"Wu, Y. et al. Highly efficient therapeutic gene editing of human hematopoietic stem cells. Nat. Med. 25, 776\u2013783 (2019).","journal-title":"Nat. Med."},{"key":"10342_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41591-020-0790-y","volume":"26","author":"J Zeng","year":"2020","unstructured":"Zeng, J. et al. Therapeutic base editing of human hematopoietic stem cells. Nat. Med. 26, 535\u2013541 (2020).","journal-title":"Nat. Med."},{"key":"10342_CR25","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1056\/NEJMoa2031054","volume":"384","author":"H Frangoul","year":"2021","unstructured":"Frangoul, H. et al. CRISPR\u2013Cas9 gene editing for sickle cell disease and \u03b2-thalassemia. N. Engl. J. Med. 384, 252\u2013260 (2021).","journal-title":"N. Engl. J. Med."},{"key":"10342_CR26","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1038\/s41591-022-01906-z","volume":"28","author":"B Fu","year":"2022","unstructured":"Fu, B. et al. CRISPR\u2013Cas9-mediated gene editing of the BCL11A enhancer for pediatric \u03b20\/\u03b20 transfusion-dependent \u03b2-thalassemia. Nat. Med. 28, 1573\u20131580 (2022).","journal-title":"Nat. Med."},{"key":"10342_CR27","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","volume":"390","author":"F Locatelli","year":"2024","unstructured":"Locatelli, F. et al. Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia. N. Engl. J. Med. 390, 1663\u20131676 (2024).","journal-title":"N. Engl. J. Med."},{"key":"10342_CR28","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","volume":"24","author":"E Haapaniemi","year":"2018","unstructured":"Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR\u2013Cas9 genome editing induces a p53-mediated DNA damage response. Nat. Med. 24, 927\u2013930 (2018).","journal-title":"Nat. Med."},{"key":"10342_CR29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.stem.2019.02.019","volume":"24","author":"G Schiroli","year":"2019","unstructured":"Schiroli, G. et al. Precise gene editing preserves hematopoietic stem cell function following transient p53-mediated DNA damage response. Cell Stem Cell 24, 551\u2013565 (2019).","journal-title":"Cell Stem Cell"},{"key":"10342_CR30","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/nbt.4192","volume":"36","author":"M Kosicki","year":"2018","unstructured":"Kosicki, M., Tomberg, K. & Bradley, A. Repair of double-strand breaks induced by CRISPR\u2013Cas9 leads to large deletions and complex rearrangements. Nat. Biotechnol. 36, 765\u2013771 (2018).","journal-title":"Nat. Biotechnol."},{"key":"10342_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09006-2","volume":"10","author":"G Cullot","year":"2019","unstructured":"Cullot, G. et al. CRISPR\u2013Cas9 genome editing induces megabase-scale chromosomal truncations. Nat. Commun. 10, 1136 (2019).","journal-title":"Nat. Commun."},{"key":"10342_CR32","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","volume":"186","author":"CA Tsuchida","year":"2023","unstructured":"Tsuchida, C. A. et al. Mitigation of chromosome loss in clinical CRISPR\u2013Cas9-engineered T cells. Cell 186, 4567\u20134582 (2023).","journal-title":"Cell"},{"key":"10342_CR33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420\u2013424 (2016).","journal-title":"Nature"},{"key":"10342_CR34","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nature24644","volume":"551","author":"NM Gaudelli","year":"2017","unstructured":"Gaudelli, N. M. et al. Programmable base editing of A*T to G*C in genomic DNA without DNA cleavage. Nature 551, 464\u2013471 (2017).","journal-title":"Nature"},{"key":"10342_CR35","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nbt.4102","volume":"36","author":"X Li","year":"2018","unstructured":"Li, X. et al. Base editing with a Cpf1\u2013cytidine deaminase fusion. Nat. Biotechnol. 36, 324\u2013327 (2018).","journal-title":"Nat. Biotechnol."},{"key":"10342_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41594-017-0004-6","volume":"25","author":"L Lei","year":"2018","unstructured":"Lei, L. et al. APOBEC3 induces mutations during repair of CRISPR\u2013Cas9-generated DNA breaks. Nat. Struct. Mol. Biol. 25, 45\u201352 (2018).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10342_CR37","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/s41587-020-0561-9","volume":"38","author":"AV Anzalone","year":"2020","unstructured":"Anzalone, A. V., Koblan, L. W. & Liu, D. R. Genome editing with CRISPR\u2013Cas nucleases, base editors, transposases and prime editors. Nat. Biotechnol. 38, 824\u2013844 (2020).","journal-title":"Nat. Biotechnol."},{"key":"10342_CR38","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.tibs.2020.06.003","volume":"45","author":"L Yang","year":"2020","unstructured":"Yang, L. & Chen, J. A tale of two moieties: rapidly evolving CRISPR\/Cas-based genome editing. Trends Biochem. Sci. 45, 874\u2013888 (2020).","journal-title":"Trends Biochem. Sci."},{"key":"10342_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41580-023-00663-2","volume":"25","author":"JS Kim","year":"2024","unstructured":"Kim, J. S. & Chen, J. Base editing of organellar DNA with programmable deaminases. Nat. Rev. Mol. Cell Biol. 25, 34\u201345 (2024).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10342_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","volume":"42","author":"A Karimian","year":"2016","unstructured":"Karimian, A., Ahmadi, Y. & Yousefi, B. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair 42, 63\u201371 (2016).","journal-title":"DNA Repair"},{"key":"10342_CR41","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/bioinformatics\/btu048","volume":"30","author":"S Bae","year":"2014","unstructured":"Bae, S., Park, J. & Kim, J. S. Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics 30, 1473\u20131475 (2014).","journal-title":"Bioinformatics"},{"key":"10342_CR42","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nbt.3852","volume":"35","author":"D Kim","year":"2017","unstructured":"Kim, D. et al. Genome-wide target specificities of CRISPR RNA-guided programmable deaminases. Nat. Biotechnol. 35, 475\u2013480 (2017).","journal-title":"Nat. Biotechnol."},{"key":"10342_CR43","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/nbt.4198","volume":"36","author":"X Wang","year":"2018","unstructured":"Wang, X. et al. Efficient base editing in methylated regions with a human APOBEC3A\u2013Cas9 fusion. Nat. Biotechnol. 36, 946\u2013949 (2018).","journal-title":"Nat. Biotechnol."},{"key":"10342_CR44","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s41588-023-01434-7","volume":"55","author":"T Mayuranathan","year":"2023","unstructured":"Mayuranathan, T. et al. Potent and uniform fetal hemoglobin induction via base editing. Nat. Genet. 55, 1210\u20131220 (2023).","journal-title":"Nat. Genet."},{"key":"10342_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35508-7","volume":"14","author":"J Liao","year":"2023","unstructured":"Liao, J. et al. Therapeutic adenine base editing of human hematopoietic stem cells. Nat. Commun. 14, 207 (2023).","journal-title":"Nat. Commun."},{"key":"10342_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.64","volume":"3","author":"TJ Cradick","year":"2014","unstructured":"Cradick, T. J., Qiu, P., Lee, C. M., Fine, E. J. & Bao, G. COSMID: a web-based tool for identifying and validating CRISPR\/Cas off-target sites. Mol. Ther. Nucleic Acids 3, e214 (2014).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10342_CR47","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.ymthe.2023.02.011","volume":"31","author":"MK Cromer","year":"2023","unstructured":"Cromer, M. K. et al. Comparative analysis of CRISPR off-target discovery tools following ex vivo editing of CD34+ hematopoietic stem and progenitor cells. Mol. Ther. 31, 1074\u20131087 (2023).","journal-title":"Mol. Ther."},{"key":"10342_CR48","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/cr.2017.111","volume":"27","author":"L Wang","year":"2017","unstructured":"Wang, L. et al. Enhanced base editing by co-expression of free uracil DNA glycosylase inhibitor. Cell Res. 27, 1289\u20131292 (2017).","journal-title":"Cell Res."},{"key":"10342_CR49","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aao4774","volume":"3","author":"AC Komor","year":"2017","unstructured":"Komor, A. C. et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci. Adv. 3, eaao4774 (2017).","journal-title":"Sci. Adv."},{"key":"10342_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1089\/crispr.2019.0001","volume":"2","author":"B Yang","year":"2019","unstructured":"Yang, B., Yang, L. & Chen, J. Development and application of base editors. CRISPR J. 2, 91\u2013104 (2019).","journal-title":"CRISPR J."},{"key":"10342_CR51","unstructured":"Taher, A., Vichinsky, E., Musallam, K., Cappellini, M. D. & Viprakasit, V. in Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT) (ed. Weatherall, D.) (Thalassaemia International Federation, 2013)."},{"key":"10342_CR52","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/jmri.22245","volume":"32","author":"P Kirk","year":"2010","unstructured":"Kirk, P. et al. International reproducibility of single breathhold T2* MR for cardiac and liver iron assessment among five thalassemia centers. J. Magn. Reson. Imaging 32, 315\u2013319 (2010).","journal-title":"J. Magn. Reson. Imaging"},{"key":"10342_CR53","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1056\/NEJMoa2215643","volume":"389","author":"A Sharma","year":"2023","unstructured":"Sharma, A. et al. CRISPR\u2013Cas9 editing of the HBG1 and HBG2 promoters to treat sickle cell disease. N. Engl. J. Med. 389, 820\u2013832 (2023).","journal-title":"N. Engl. J. Med."},{"key":"10342_CR54","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","volume":"390","author":"H Frangoul","year":"2024","unstructured":"Frangoul, H. et al. Exagamglogene autotemcel for severe sickle cell disease. N. Engl. J. Med. 390, 1649\u20131662 (2024).","journal-title":"N. Engl. J. Med."},{"key":"10342_CR55","doi-asserted-by":"publisher","first-page":"5245","DOI":"10.1093\/nar\/18.17.5245","volume":"18","author":"S Fucharoen","year":"1990","unstructured":"Fucharoen, S., Shimizu, K. & Fukumaki, Y. A novel C-T transition within the distal CCAAT motif of the G\u03b3-globin gene in the Japanese HPFH: implication of factor binding in elevated fetal globin expression. Nucleic Acids Res. 18, 5245\u20135253 (1990).","journal-title":"Nucleic Acids Res."},{"key":"10342_CR56","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1182\/blood.V77.5.1124.1124","volume":"77","author":"R Oner","year":"1991","unstructured":"Oner, R., Kutlar, F., Gu, L. H. & Huisman, T. H. The Georgia type of nondeletional hereditary persistence of fetal hemoglobin has a C\u2192T mutation at nucleotide-114 of the A\u03b3-globin gene. Blood 77, 1124\u20131125 (1991).","journal-title":"Blood"},{"key":"10342_CR57","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.1365-2141.1994.tb03284.x","volume":"86","author":"PI Motum","year":"1994","unstructured":"Motum, P. I., Deng, Z. M., Huong, L. & Trent, R. J. The Australian type of nondeletional G\u03b3-HPFH has a C\u2192G substitution at nucleotide -114 of the G\u03b3 gene. Br. J. Haematol. 86, 219\u2013221 (1994).","journal-title":"Br. J. Haematol."},{"key":"10342_CR58","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3109\/03630269908996160","volume":"23","author":"S Zertal-Zidani","year":"1999","unstructured":"Zertal-Zidani, S. et al. A novel C\u2192A transversion within the distal CCAAT motif of the G\u03b3-globin gene in the Algerian G\u03b3\u03b2+-hereditary persistence of fetal hemoglobin. Hemoglobin 23, 159\u2013169 (1999).","journal-title":"Hemoglobin"},{"key":"10342_CR59","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/394295","volume":"2013","author":"JA Ribeil","year":"2013","unstructured":"Ribeil, J. A. et al. Ineffective erythropoiesis in \u03b2-thalassemia. Sci. World J. 2013, 394295 (2013).","journal-title":"Sci. World J."},{"key":"10342_CR60","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41588-022-01257-y","volume":"55","author":"S Cancellieri","year":"2023","unstructured":"Cancellieri, S. et al. Human genetic diversity alters off-target outcomes of therapeutic gene editing. Nat. Genet. 55, 34\u201343 (2023).","journal-title":"Nat. Genet."},{"key":"10342_CR61","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1126\/science.ade6967","volume":"381","author":"L Breda","year":"2023","unstructured":"Breda, L. et al. In vivo hematopoietic stem cell modification by mRNA delivery. Science 381, 436\u2013443 (2023).","journal-title":"Science"},{"key":"10342_CR62","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-1-62703-128-8_17","volume":"946","author":"B Wognum","year":"2013","unstructured":"Wognum, B., Yuan, N., Lai, B. & Miller, C. L. Colony forming cell assays for human hematopoietic progenitor cells. Methods Mol. Biol. 946, 267\u2013283 (2013).","journal-title":"Methods Mol. Biol."},{"key":"10342_CR63","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/S0301-472X(00)00555-5","volume":"28","author":"LA Mathias","year":"2000","unstructured":"Mathias, L. A. et al. Ineffective erythropoiesis in \u03b2-thalassemia major is due to apoptosis at the polychromatophilic normoblast stage. Exp. Hematol. 28, 1343\u20131353 (2000).","journal-title":"Exp. Hematol."},{"key":"10342_CR64","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature13614","volume":"514","author":"JB Arlet","year":"2014","unstructured":"Arlet, J. B. et al. HSP70 sequestration by free \u03b1-globin promotes ineffective erythropoiesis in \u03b2-thalassaemia. Nature 514, 242\u2013246 (2014).","journal-title":"Nature"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10342-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10342-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10342-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:02:35Z","timestamp":1779278555000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10342-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":64,"journal-issue":{"issue":"8115","published-print":{"date-parts":[[2026,5,21]]}},"alternative-id":["10342"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10342-9","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"17 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C., L.Y. and B.Y. are scientific cofounders of CorrectSequence Therapeutics, a company that uses gene-editing technologies, and the members of its scientific advisory board. X.M., L.W. and Y.\u00a0Li are employees of CorrectSequence Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}